InvestSMART

Invex Therapeutics Ltd (ASX:IXC)

ALERT: Price-sensitive ASX Announcement for IXC
Current share price for IXC : $0.095 -0.005 (-5%)+
Announcement
Release
24 Apr 2026 12:13PM
Price at Release
$0.100
Full Release
download
Summary
Invex Therapeutics Ltd, an Australian biopharmaceutical company, focuses on the repurposing of Exenatide for treating neurological conditions involving raised intracranial pressure. In their latest quarterly report, Invex highlighted their ongoing R&D efforts, particularly with Tessara Therapeutics, demonstrating Exenatide's potential therapeutic benefits in early Alzheimer's Disease models. Financially, the company ended the quarter with $4.517 million in cash, while experiencing decreased corporate costs and R&D expenses amounting to $53,000. Throughout the quarter, Invex reported no significant investment or financing activities, and noted corporate changes including the resignation of Ms. Carla Healy as Joint Company Secretary.
Key Points
  • Invex Therapeutics focuses on developing Exenatide for neurological conditions related to raised intracranial pressure.
  • Exenatide has shown promising results in reducing neurofilament light chain levels and pro-inflammatory cytokines in models simulating Alzheimer's Disease.
  • The company's cash balance at the end of the quarter was $4.517 million with operating cash outflows of $79,000.
  • Payments for research and development activities amounted to $53,000 during the quarter.
  • Corporate costs decreased significantly compared to the previous quarter.
  • No new investment or financing activities were reported during the quarter.
  • The company held its Annual General Meeting on 17 February 2026.
  • Ms. Carla Healy resigned as Joint Company Secretary on 23 March 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.